Envisia’s ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).